Information on COVID-19
Learn more about COVID-19, information about previously scheduled appointments and what you can do to help protect your child and family. View COVID-19 information.
Riley at IU Health Facilities have implemented visitor restrictions to help minimize the spread of COVID-19, flu and other respiratory viruses. View visitor restrictions.
Information on Previously Scheduled Outpatient Appointments
To ensure the health and safety of all our patients and team members during the coronavirus (COVID-19) pandemic, we’re making adjustments to some of our outpatient appointments. View updates to outpatient appointments.
Free Virtual Coronavirus Screenings
IU Health has launched a virtual clinic to offer individuals in Indiana regardless of age free coronavirus (COVID-19) screenings. View screening details.
Información sobre el COVID-19
Obtenga más información acerca del COVID-19, incluyendo las preguntas más frecuentes y lo que puede hacer para ayudar a protegerse y proteger a su familia. Ver información del COVID-19.
Restricciones para visitantes
Las instalaciones de salud de IU Health han implementado restricciones a los visitantes para ayudar a minimizar la propagación del COVID-19, la gripe y otros virus respiratorios. Ver restricciones para visitantes.
Información sobre citas ambulatorias previamente programadas
Para asegurar la salud y la seguridad de todos nuestros pacientes y empleados durante la pandemia del coronavirus (COVID-19), estamos haciendo ajustes en algunas de nuestras citas ambulatorias. Ver actualizaciones de citas ambulatorias.
Exámenes de coronavirus virtuales gratuitos
IU Health ha lanzado una clínica virtual para ofrecer a las personas en Indiana, independientemente de la edad, evaluaciones virtuales para la detección del coronavirus (COVID-19). Ver detalles de la evaluación.
aren’t many teenagers who wouldn’t trade the world to be exactly like the kids
around them. That’s especially true for teens that test positive for hepatitis C, most often passed to them at birth through their mothers’ infection. These
kids may look as healthy as their peers, often showing few symptoms of the
virus. Despite appearances, hepatitis C lurks over them like a dark cloud, as
some patients with hepatitis C can develop cirrhosis of the liver, liver
failure and an increased risk for liver cancer later in life. In fact,
hepatitis C is the cause of an estimated 50 percent of adult liver transplants.
Twenty years ago, there weren’t many drugs to treat the virus, and the few drugs that did exist were expensive. Administered in shots, they often made patients very ill and only conquered the virus 15 percent of the time.
For almost two decades, Jean Molleston, MD, has been working with Riley at IU Health patients in clinical trials designed to find better hepatitis C drug therapies for children. During the same period, clinical trials with adults—always the first group of patients to test new medicines—were making headway.
“For adults, there are now these oral drug regimens that work over 90 percent of the time,” Molleston says. “They’re amazing.” At a cost of approximately $100,000 per patient, the drugs are still expensive, but they cause fewer side effects, and the adults who take them are most often virus-free within 12 weeks. Unfortunately, the only FDA-approved therapy for kids has a success rate of just 55 percent.
That story is changing through a handful of pediatric clinical trials Molleston supports in her research role at Riley at IU Health and the Indiana University School of Medicine. The studies are designed to see how children react to drugs that are only approved for adults. “These clinical trials give children access to drugs to treat their virus and a wonderful chance of clearing their hepatitis C,” she says.
Delivering the news that the drugs have worked is one of the most exciting parts of Molleston’s job. “It’s treatment that they couldn’t otherwise get, and when they clear that virus, it’s done, it’s gone,” she says. The knowledge that they are clear lifts a huge burden from kids who often feel very defined by their condition. They no longer have to be checked at frequent intervals or live in dread of having their illness get worse.
Molleston started as a bench scientist who thought she wanted to spend her career doing experiments in a lab. In the early 1990s, she participated in one of her first clinical trials for drugs to treat hepatitis B and soon realized that she really liked working with patients in clinical research. Since making the switch, she has been part of many studies organized by national pediatric research networks, often supported by the National Institutes of Health.
In that length of time, Molleston has witnessed a lot of bravery and motivation among her teen patients, especially those who weathered the earliest clinical trials. Many adults were not able to work while they were on these drugs. “I remember one of my patients who would get her shot on a Friday and participate in marching band the next day,” says Molleston. Their strength has made a smoother path for the kids who enroll in today’s clinical trials, which are designed to bring better drugs to children at younger ages.
Learn more about clinical trials at Riley at IU Health by visiting our resource page for parents and caregivers.